Dual-subtype feline immunodeficiency virus vaccine provides 12 months of protective immunity against heterologous challenge

The duration of immunity of the dual-subtype feline immunodeficiency virus (FIV) vaccine, Fel-O-Vax FIV, for protection against subtype-B FIV was assessed in this study. Vaccinated cats along with controls were challenged with FIVFC1, a subtype-B FIV strain, 54 weeks after the final vaccination, and monitored for 46–48 weeks for provirus and viral RNA in peripheral blood, provirus in lymphoid organs, and CD4:CD8 ratios. Results of provirus detection in peripheral blood and lymphoid organs and plasma viral RNA loads showed that 10/14 vaccinated cats were fully protected for 48 weeks against infection with FIVFC1 whereas 5/5 controls were persistently infected with FIVFC1. CD4:CD8 inversions were noted in association with FIV infection and viral loads were not significantly different between FIV infected controls and the unprotected vaccinated animals.

[1]  H. M. Scott,et al.  Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection among cats in North America and risk factors for seropositivity. , 2006, Journal of the American Veterinary Medical Association.

[2]  C. Greene.  Infectious Diseases of the Dog and Cat , 1990, Australian Veterinary Journal.

[3]  E. Uhl,et al.  Advances in FIV vaccine technology. , 2008, Veterinary immunology and immunopathology.

[4]  T. Tanabe,et al.  Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine. , 2004, Vaccine.

[5]  Kayoko Sato,et al.  Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats. , 2005, Veterinary microbiology.

[6]  T. Tanabe,et al.  Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates , 2001, AIDS.

[7]  J. Neil,et al.  Infection with feline immunodeficiency virus is followed by the rapid expansion of a CD8+ lymphocyte subset. , 1993, Immunology.

[8]  E. Sato,et al.  Dual-subtype FIV vaccine (Fel-O-Vax® FIV) protection against a heterologous subtype B FIV isolate , 2005, Journal of feline medicine and surgery.

[9]  N. Cordonnier,et al.  Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS. , 2009, Vaccine.

[10]  Jennifer L. Garcia.  Infectious Diseases of the Dog and Cat, 2nd ed , 1999 .

[11]  D. Champ,et al.  Efficacy and safety of a feline immunodeficiency virus vaccine , 2004, Animal Health Research Reviews.

[12]  D. Klein,et al.  Phylogenetic analysis of feline immunodeficiency virus in Central Europe: a prerequisite for vaccination and molecular diagnostics. , 2003, The Journal of general virology.

[13]  C. Aizawa,et al.  Effect of dual-subtype vaccine against feline immunodeficiency virus infection , 1997, Veterinary Microbiology.

[14]  W. Tompkins,et al.  Induction of IL-2 and lymphokine activated killer cells in the cat. , 1987, Veterinary immunology and immunopathology.

[15]  V. Baladandayuthapani,et al.  Pathogenesis of a Texas feline immunodeficiency virus isolate: an emerging subtype of clade B. , 2006, Veterinary microbiology.